This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Natalie has worked with private hospitals and clinics in relation to medical malpractice claims, and assisted on cases involving medical devices product liability and clinicaltrials. The Article. Our seminar on Wednesday 6 March will look at the use of medicinal cannabis in more detail. Senior Associate. +44
The article argues for the implementation of nuanced risk assessment strategies for handling psychedelics in medicine, and predicts an expansion of psychedelic substances into mainstream medicine. Dr. Johnson will be presenting “Psychedelics and behavior change” at the Harvard/McLean Hospital’s Neuroscience Seminar Series.
Using a content analysis approach, we investigated articles about medicinal cannabis from 2000 to the end of 2019 in the Medical Journal of Australia, Australian Doctor , Medical Observer , Australian Journal of General Practice , Australian Family Physicia n , and Australian Medicine. Conclusions. Background.
fast-tracked clinicaltrials of GW Pharmaceuticals’ 98 percent CBD drug, Epidiolex. There haven’t been enough clinicaltrials and there never will be,” said Mr. Clarke, the cannabis seed collector. Read the full article here. And with this group, finally, it seemed to be coming together.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content